Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy
Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy
More from Archive
More from Pink Sheet
• By
Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.
• By
England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.
• By
The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.